Related Experiment Video
Updated: Mar 7, 2026

Transcranial Direct Current Stimulation tDCS for Memory Enhancement
Published on: September 18, 2021
Assessing quality of life in Alzheimer's disease: Implications for clinical trials
Kristin Kahle-Wrobleski1, Wenyu Ye2, David Henley1
1Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
Introduction:
Characterization of the quality of life (QOL) in Alzheimer's disease (AD) scale within the context of a clinical trial may inform its applicability in future trials.
Methods:
Using data from 1322 patients enrolled in two phase-III studies (EXPEDITION 1 [NCT00905372] and 2 [NCT00904683]) of intravenous solanezumab in outpatients with mild AD dementia, correlations between patient- and caregiver-assessed QOL and between QOL and clinical outcome measures were examined. Longitudinal effects of solanezumab over 80 weeks were explored, controlling for patient and caregiver baseline characteristics.
Results:
Caregivers rated patients' QOL worse than did patients themselves. Patients' QOL was correlated, albeit modestly, with clinical/health measures. Patients' QOL changed minimally over 80 weeks, although a treatment effect of solanezumab on QOL was detected.
Discussion:
Further investigations are needed to determine the optimal measures with which to quantify and qualify QOL of patients with mild AD.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Dementia
The progression of dementia is generally gradual....
Pharmacodynamics in Geriatric Patients: Effects of Age
Drug Dosing: Geriatric Patients
Clinical Trials: Overview

